Pharma BD Deal Intelligence
HBM Holdings Limited (Harbour BioMed) / Yantai Lannacheng Biotechnology Co., Ltd.
2025 · Co-Development · Complete
Harbour BioMed entered a long-term strategic collaboration with Yantai Lannacheng Biotechnology (Lannacheng) to jointly advance next-generation radionuclide drug conjugates (RDCs) for oncology. The collaboration pairs Harbour BioMed's fully human antibody discovery platforms with Lannacheng's radiopharmaceutical R&D and commercialization capabilities. No financial terms were disclosed.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Dec 29, 2025
- Deal type Co-Development
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals